EUVIMEDEUVIMED entdecken
Crossref

Regulatory Toxicological Evaluation of Targeted Nanocarrier-Based Drug Delivery Systems for Breast and Ovarian Cancer Therapy

Shilpashree Bettadapura Muralidhar, Rajani Rokade, Durga Paswan, Parameswaran Namboothiri, RamGopal Singh, Dinesh Kumar Bajpai

International Journal of Drug Delivery Technology · 22.05.2026 · 16 (30s)

DOI: 10.25258/ijddt.16.46s.18 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 22.05.2026. Verfasst von Shilpashree Bettadapura Muralidhar und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted nanocarrier-based drug delivery systems have become one of the most significant developments in modern oncology, especially in the treatment of breast and ovarian cancer, where therapeutic selectivity and safety have continued to be a clinical problem. Traditional chemotherapeutic regiments are usually limited in tumour specificity, dose limiting toxicity and poor pharmacokinetic control that all undermine the treatment effects. These limitations are overcome by nanocarrier-based delivery platforms on the basis of the accurate modulation of drug biodistribution, controlled release kinetics, and ligand-mediated tumour targeting to maximize therapeutic indices and reduce systemic exposure. The present review critically analyzes the designing, functional performance, and regulatory toxicological concerns that can be related to the targeted nanocarrier drug delivery system to treat breast and ovarian cancer. The focus is put on the interdependence of the physicochemical design parameters, biological interactions, biodistribution profiles, and safety outcomes. The essential nanocarrier systems, functionalization at the surface, and stimuli-responsive release systems are outlined and their implication in the pharmacokinetic, toxicity, and clinical translatability of the drugs. Simultaneously, regulatory toxicology is also emphasized as a safety-by-design approach that incorporates the toxicological analysis of the product into the early formulation stage, manufacturing scale-up, and quality control. This article promotes the significance of safety-based and holistic nanocarrier-engineering, by bridging the delivery efficiency through the toxicological acceptability and regulatory preparedness.

Zitieren

APA

Muralidhar, S. B., Rokade, R., Paswan, D., Namboothiri, P., Singh, R., & Bajpai, D. K. (2026). Regulatory Toxicological Evaluation of Targeted Nanocarrier-Based Drug Delivery Systems for Breast and Ovarian Cancer Therapy. International Journal of Drug Delivery Technology, 16(30s). https://doi.org/10.25258/ijddt.16.46s.18

Vancouver

Muralidhar SB, Rokade R, Paswan D, Namboothiri P, Singh R, Bajpai DK. Regulatory Toxicological Evaluation of Targeted Nanocarrier-Based Drug Delivery Systems for Breast and Ovarian Cancer Therapy. International Journal of Drug Delivery Technology. 2026;16(30s). doi:10.25258/ijddt.16.46s.18

BibTeX
@article{Muralidhar2026,
  author = {Muralidhar, Shilpashree Bettadapura and Rokade, Rajani and Paswan, Durga and Namboothiri, Parameswaran and Singh, RamGopal and Bajpai, Dinesh Kumar},
  title = {Regulatory Toxicological Evaluation of Targeted Nanocarrier-Based Drug Delivery Systems for Breast and Ovarian Cancer Therapy},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {30s},
  doi = {10.25258/ijddt.16.46s.18}
}
Kostenlos starten →